Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
INTRAVENOUS FLUNITRAZEPAM IN THE TREATMENT OF ALCOHOL-WITHDRAWAL DELIRIUM
Autore:
PYCHA R; MILLER C; BARNAS C; HUMMER M; STUPPACK C; WHITWORTH A; FLEISCHHACKER WW;
Indirizzi:
INNSBRUCK UNIV CLIN,DEPT PSYCHIAT,BIOL PSYCHIAT RES UNIT,ANICHSTR 35 A-6020 INNSBRUCK AUSTRIA INNSBRUCK UNIV CLIN,DEPT PSYCHIAT,BIOL PSYCHIAT RES UNIT,ANICHSTR 35 A-6020 INNSBRUCK AUSTRIA
Titolo Testata:
Alcoholism, clinical and experimental research
fascicolo: 4, volume: 17, anno: 1993,
pagine: 753 - 757
SICI:
0145-6008(1993)17:4<753:IFITTO>2.0.ZU;2-X
Fonte:
ISI
Lingua:
ENG
Soggetto:
TREMENS; SEDATION;
Keywords:
ALCOHOLISM; ALCOHOL WITHDRAWAL DELIRIUM; DELIRIUM-TREMENS; TREATMENT; BENZODIAZEPINES; FLUNITRAZEPAM;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
23
Recensione:
Indirizzi per estratti:
Citazione:
R. Pycha et al., "INTRAVENOUS FLUNITRAZEPAM IN THE TREATMENT OF ALCOHOL-WITHDRAWAL DELIRIUM", Alcoholism, clinical and experimental research, 17(4), 1993, pp. 753-757

Abstract

Alcohol withdrawal delirium (AWD) requires treatment with an adequatesedative, anticonvulsant, and antipsychotic agent next to general intensive care measures. Optimal medication should have a rapid onset of action and the possibility of parenteral application. A specific antagonist should be available. Flunitrazepam is a benzodiazepine that fulfills all these criteria. Twenty five patients suffering from AWD (meanage 45 years) took part in an open trial and underwent treatment withinfusions of flunitrazepam (concentration: 8 mg/250 ml NaCl; speed, 250 ml/hr). Psychopathological, vegetative, and vital parameters were assessed every hour. All patients survived. They were treated with a mean total dose (SD) of 83.9 (45.4) mg of flunitrazepam (1.3 mg/kg body weight), which induced sedation 13.2 (5.3) min after the initiation ofintravenous treatment. The mean duration of AWD (85.1 +/- 39.4 hr) corresponded to other studies, whereas the frequency of preexisting and concomitant diseases was higher (92%) in our patients. A patient who suffered from bronchitis and had a nasopharyngeal tamponade showed severe respiratory depression after having received 4 mg of flunitrazepam. This complication remitted immediately when 0.5 mg of flumazenil was given intravenously. No epileptic manifestation was observed during the treatment or after discontinuation of flunitrazepam. Vegetative and psychopathological symptoms (tremor, sweating, hallucinations, confusion, and restlessness) remitted rapidly. Our data suggest that intravenous flunitrazepam can be an efficacious and safe alternative to traditional treatment strategies of AWD.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/03/20 alle ore 14:26:20